Events
-
2022/11/15 Correctseq
Nov 10, 2022, Dr. Mou, CEO of Correctseq, won the Pharma Big Star prize of Annual Influential Enterprise Leaders of Chinese CGT Field in 2022 in Shanghai (Minhang) Biomedical Industry Innovation Summit Award Ceremony of 2022. The prize list was selected by MedClub of emedclub.com together with industry experts.
-
2022/10/15 e-Safe
Oct 15, 2022, the Fourth Cell and Gene Therapy Non-Clinical Evaluation Salon organized by Drug Toxicology Committee of Chinese Pharmacological Society, Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, and Tsinghua University, was successfully held online. The salon’s theme was Oncolytic Viruses, Gene Editing and R&D Cases. Dr. Mou, CEO of Correctseq, participated in the salon and made a speech titled How to Create Innovative Gene Editing System and Make Its Clinical Application Safety. The Chairman of Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, Dr. Mingyang Liao participated in the salon and make an opening speech. The Chairman of the salon, Deputy Editor-in-Chief of Tsinghua University Press, Yu Sun, and the Chairman of the salon, Deputy Chairman and Secretary-General of Drug Toxicology and Safety Evaluation Committee of Chinese Society of Toxicology, Vice President of Suzhou Pharmaceutical Research Institute, Quanjun Wang hosted the salon.
-
2022/08/05 Correctseq
On Aug 2-4, 2022, National Medical Products Administration Institute of Executive Development hold Drug Researcher Conference online. Dr Lijie Wang, head of CorrectSequence Therapeutics (Correctseq) Gene Editing Platform, was invited to attend the conference and made a speech on the topic of “the Latest Advances and Clinical Applications of Gene Editing”. (Online Live| Drug Researcher Conference( Topic: Biologics Registration Regulations and Applications)
-
2022/07/13 Correctseq
CorrectSequence's Base Editing Tool Authorized by Overseas Patent
July 13, 2022(USA time), tBE(transformer Base Editor), developed by the scientific co-founders of CorrectSequence Therapeutics(Correctseq), is authorized by USPTO formally(United States Patent and Trademark Office). It’s the Chinese first base editing tool authorized by overseas patents. Correctseq has got the worldwide exclusive license of tBE from ShanghaiTech University, becoming the exclusive biopharmaceutical company that owns the global rights and interests of the underlying platform-based base editing system patent. The First IND pipeline for thalassemia of Correctseq is well underway, using tBE to create a creative base editing therapy. Correctseq is the Chinese first biopharmaceutical company which transforms the Chinese self-developed base editing tool into a creative base editing therapy. Correctseq has already got the worldwide exclusive license of eBE, which is the first base editing tool authorized by Chinese patents. At the same time, Correctseq has applied PCT for several base editing tools.
-
2022/07/03 Correctseq
July 2, 2022, Prof. Bei Yang, co-founder of CorrectSequence Therapeutics (Correctseq), participated in Antigen & Antibody Discovery and Precision Medicine Conference and made a speech titled “Antigenic Mapping by HDX-MS Reveals Sites of Vulnerability on α-HCoVs Spike Protein”. 3 academicians, 10 experts shared their newest research in the field of antigen & antibody. The conference was held online and attracted 6600 attendees.
-
2022/06/17 Correctseq
June 15, 2022, Correctseq got prize of “Top 10 Gene Therapy Companies of 2022 Future Healthcare VB100-Best Performing Companies in Value Fields” from VBDATA.CN, which held a conference titled“2022 Future Healthcare VB100”from June 14 to 18, 2022. Correctseq is considered as the most potential company in the gene therapy fields because of its innovative gene editing technology by investors and medias.
-
2022/06/16 Correctseq
Correctseq Gets Prize of ”2022 Top 50 Biotech Innovation Companies”
June 15, 2022, Correctseq got prize of “2022 Top 50 Biotech Innovation Companies” from KPMG. On the prize list, more than half of companies have 5 years histories, 89% companies have more than 3 years histories, only 4 companies have less than 2 years histories and Correctseq is one of them. Correctseq is evaluated to be the most potential company in the gene therapy fields because of its innovative gene editing technology.
-
2022/05/01 Correctseq
On May 1, 2022, CorrectSequence Therapeutics (Correctseq), a pioneer gene editing biotechnology company, announced that Dr. Guang Gao was invited to serve as a long-term special consultant for global quality standards, to guide the global application of Correctseq R&D pipeline and the establishment of global quality systems in line with China, USA and European standards.